Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm PK and efficacy/safety study of human fibrinogen in adults with congenital hypofibrinogenemia or afibrinogenemia
CTR20262442Phase 3Active
- Sponsor
- Sinopharm Kunming Blood Products
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Fibrinogen human in fibrinogen deficiency, congenital afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, sponsored by Sinopharm Kunming Blood Products. Started Jun 2026; status: active.
02
Drugs
Fibrinogen human
03
Conditions
fibrinogen deficiencycongenital afibrinogenemiahypofibrinogenemiadysfibrinogenemia
Beyond the preview
Go deeper on CTR20262442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262442.